GENFLEET-B (02595.HK), a biopharmaceutical company focused on oncology, autoimmune, and inflammatory diseases, is conducting its IPO in Hong Kong. The company plans to globally offer 77.6 million H shares, with 10% allocated for the Hong Kong public offering and 90% for the international placement.

The offer price is HKD20.39 per share, and the IPO aims to raise approximately HKD1.582 billion. The entry fee for each board lot size (200 shares) approximates HKD4,119.13. The IPO period starts today (11th) and will end at noon next Tuesday (16th), with the listing expected next Friday (19th). CITIC Securities acts as the sole sponsor.

Based on the offer price of HKD20.39 per share, the net proceeds are estimated to be approximately HKD1.444 billion. This IPO attracted nine cornerstone investors, including RTW Fund, TruMed, OrbiMed, UBS Asset Management (Singapore) Ltd., Vivo Fund, CITIC SEC (06030.HK) 's CITIC Securities International Capital Management. They collectively subscribed for shares equivalent to approximately USD100 million.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-09-10 16:25.)